Search Results

Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024.

Dyadic International, Inc. announced that its management will be attending the following industry events during the month of April 2024.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial result for the year end 2023 and highlighted recent Company progress.

Dyadic International, Inc. announced that its management will be attending the following industry events during the month of March 2024.

Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI) today announced the online publication of the manuscript “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models” in Nature Communications (“Springer-Nature”), an international journal publishing peer-reviewed research in all fields of science and technology.